Cooper Gregory M
HudsonAlpha Institute for Biotechnology, Huntsville, Alabama 35806, USA.
Genome Res. 2015 Oct;25(10):1423-6. doi: 10.1101/gr.190116.115.
Human genome sequencing is routine and will soon be a staple in research and clinical genetics. However, the promise of sequencing is often just that, with genome data routinely failing to reveal useful insights about disease in general or a person's health in particular. Nowhere is this chasm between promise and progress more evident than in the designation, "variant of uncertain significance" (VUS). Although it serves an important role, careful consideration of VUS reveals it to be a nebulous description of genomic information and its relationship to disease, symptomatic of our inability to make even crude quantitative assertions about the disease risks conferred by many genetic variants. In this perspective, I discuss the challenge of "variant interpretation" and the value of comparative and functional genomic information in meeting that challenge. Although already essential, genomic annotations will become even more important as our analytical focus widens beyond coding exons. Combined with more genotype and phenotype data, they will help facilitate more quantitative and insightful assessments of the contributions of genetic variants to disease.
人类基因组测序已成为常规操作,并且很快将成为研究和临床遗传学的主要手段。然而,测序的前景往往也仅止于此,基因组数据通常无法揭示有关一般疾病或特定个人健康状况的有用见解。在“意义未明的变异体”(VUS)这一命名中,承诺与进展之间的差距最为明显。尽管它发挥着重要作用,但仔细审视VUS会发现,它是对基因组信息及其与疾病关系的模糊描述,表明我们甚至无法对许多基因变异所带来的疾病风险做出粗略的定量断言。从这个角度出发,我将讨论“变异体解读”的挑战以及比较基因组学和功能基因组学信息在应对这一挑战中的价值。尽管基因组注释已经至关重要,但随着我们的分析重点从编码外显子扩展,它将变得更加重要。与更多的基因型和表型数据相结合,它们将有助于更定量、更有见地地评估基因变异对疾病的影响。